Walnut (Juglans regia L.): A Comprehensive Reference
1. Identity and Botanical Classification
Botanical name: Juglans regia L. The botanical name Juglans regia means "the royal nut of Jupiter." Specifically, "Juglans" means "Jupiter's nut" and "regia" means "royal."
Walnuts are seeds with a hard shell from the genus Juglans, which includes J. mandshurica, J. regia, J. sinensis, J. cathayensis, J. nigra, and J. sigillata. The most commercially and medicinally significant species are described below:
- Juglans regia L. — the Persian or English walnut — is a famous member of the genus broadly cultivated for the commercial high added value of its seeds. It is a relatively nutritious food rich in bioactive natural products, a crucial tree nut, and an integral part of Mediterranean nutrition; it is also used for medicinal purposes.
- Juglans nigra — the eastern black walnut — is a deciduous tree indigenous to eastern North America, where it is grown in places such as South Dakota in the United States.
- Juglans mandshurica Maxim. is a deciduous tree widely distributed in northeastern Asia. Besides its edible fruit, its green husk was used in folk medicine for its antioxidant, antitumor, and antibacterial properties.
Juglans regia is botanically classified under the angiosperm family Juglandaceae. The walnut is an edible drupaceous nut recognized worldwide for its nutritious and health-beneficial properties. This widely spread deciduous tree grows natively and commercially in Europe, Asia, and the eastern and southern parts of the United States, primarily for quality timber and the edible nut.
It is recognized by diverse names around the world and is called Persian walnut in English, Akhrot in Hindi, Doon in local Kashmiri, and Gardhghani in Unani.
Common forms and preparations: The plant is used in multiple forms. In modern times, the walnuts (kernels), leaves, and hulls (husks) are most commonly used. The husk is the green fleshy covering over the walnut shell. Medicinally, husks are used when they have turned from green to black and are beginning to break down. Within Juglandaceae genera, secondary metabolites including tetralones, naphthoquinones, and diarylheptanoids are considered useful chemotaxonomic markers for characterizing the family's species. Commercial and research preparations include whole raw or roasted kernels, walnut oil cold-pressed from the kernel, powdered walnut husk extracts, leaf preparations (dried or infused), and standardized polyphenol extracts.
2. Traditional and Historical Use
The first people to cultivate walnuts were the ancient Greeks, who used them not only for food, but also as medicine and dyes for hair, wool, and cloth. The Romans, imitators of the Greeks, discovered their merits and were willing to pay dearly for the luxury of serving them. In the ruins of Pompeii, whole, unshelled walnuts were among the foods on the table at the Temple of Isis on the day Mount Vesuvius erupted (24 August, 79 CE).
Walnuts are mentioned in the principal Roman treatises on agriculture: De Re Rustica (Varro), De Re Rustica (Columella), and Naturalis Historia. Pliny the Elder, in his Naturalis Historia, suggested applying walnut kernels chewed by a fasting man on a wound inflicted by a rabid dog to heal it. Walnut oil was prescribed for colic and to soothe the intestine. Green walnut juice diluted in warm water was recommended as a mouthwash and to stop diarrhoea, while green walnut boiled with sugar was used to relieve constipation.
Dioscorides, Greek author of Materia Medica (a five-volume medical encyclopedia), mentions the walnut several times and laid out a number of conditions that could be remedied by consuming walnuts mixed with other ingredients. During the next two millennia, many of these recommendations would appear repeated in different medical works. In the eleventh century, the Persian physician Ibn Sīnā wrote in his medical treatise Canon of Medicine many of the same remedies given by Dioscorides more than a thousand years earlier; he also wrote that walnuts could be preserved for extended periods by applying a coating of sugar.
Historians believe that from Kashmir, the walnut was introduced to China during the Han dynasty at some point between 206 BC and 220 AD. Other parts of the walnut plant beyond the kernel were employed as traditional Chinese medicines. In Chinese traditional medicine, the walnut kernel (Hu Tao Ren) was recorded by Ming dynasty herbalist Li Shizhen for properties including support of kidney, lung, and large intestine function. Various groups have used different parts of walnuts in traditional medicine — leaves to repel mosquitoes and kill lice, and for itching, acne, frostbite, and rheumatism. The nut itself has been used to help with memory, as an aphrodisiac, for colds, and to relieve constipation, as well as for dandruff, rheumatism, muscle pain, diabetes, and failing eyesight.
The use of black walnut (J. nigra) hulls dates back to ancient times, particularly among Native American tribes, who recognized the tree's medicinal properties. Black walnut was revered not only for its edible nuts but also for its hulls.
In fourteenth-century France, walnuts were among the list of desserts served during royal banquets, where they were preserved in a mixture of honey and spices. In the UK, the first record of the arrival of walnuts dates to the mid-sixteenth century, where they were normally served at the end of a meal with pork or Stilton cheese.
3. Key Constituents and Active Compounds
3.1 Lipids and Fatty Acids
Walnuts are rich in the polyunsaturated fatty acids linoleic acid and α-linolenic acid (ALA) at 52.4% and 12.5% of kilocalories, respectively. Of the different types of nuts, walnuts are especially rich in linoleic acid (18:2n–6), α-linolenic acid (ALA, 18:3n–3), polyphenols, L-arginine, and magnesium — a unique phytochemical composition. The oil of the walnut kernel contains major fatty acids including oleic acid, linoleic acid, and linolenic acids.
Walnuts contain PUFAs, particularly alpha-linolenic acid (ALA), which is metabolized to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the liver.
3.2 Polyphenols and Ellagitannins
Walnut phenolics are mostly of the non-flavonoid type belonging to the ellagitannin, or hydrolyzable tannins, category. It is estimated that aglycone and glycosylated ellagic acid accounts for 64–75% of total phenols in walnuts. The walnut pellicle (inner skin) contains high levels of polymeric non-flavonoid hydrolyzable tannins (ellagitannins), but small amounts of flavan-3-ol monomers or catechins.
Walnuts provide polyunsaturated fatty acids (PUFAs, approximately 47–62% of total fat) with notable levels of alpha-linolenic acid (ALA), polyphenols (especially ellagitannins like pedunculagin and ellagic acid precursors), dietary fiber, vitamins (e.g., folate, vitamin E in the γ-tocopherol form), minerals (magnesium, potassium), melatonin, and amino acids (particularly L-arginine).
Polyphenols in walnuts — including quercetin and its glycosides, ellagic acid and ellagitannins, and cyanidin and proanthocyanidins — exert antioxidant action through multiple mechanisms, including activation of the Nrf2/ARE (nuclear factor erythroid 2-related factor 2/antioxidant response element) pathway. By this pathway, polyphenols increase the activity of antioxidant and detoxifying enzymatic systems and down-regulate the nuclear factor kappa B (NF-κB) pathway, which is directly implicated in the inflammatory response. Tocopherols, tocotrienols, n-3 PUFAs, and n-6 PUFAs from walnuts can also inhibit the NF-κB pathway by activation of Nrf2/ARE.
3.3 Juglone (Naphthoquinone)
Juglone (5-hydroxyl-1,4-naphthoquinone) is a phenolic compound found in walnuts. Because of the antioxidant capacities of phenolic compounds, juglone may serve to combat oxidative stress, thereby protecting against the development of various conditions. The plant source of juglone, Juglans regia, has been found to possess an anticancer capacity; accordingly, the isolated active chemical constituent juglone has been investigated in different human cancer cell lines. Published data reveal that the cancer-related inhibitory effects of juglone are associated with enhanced reactive oxygen species (ROS) production and lipid peroxidation. These juglone findings are primarily preclinical (in vitro and animal studies) and have not yet been translated into confirmed human clinical outcomes.
3.4 Diarylheptanoids, Quinones, and Other Phytochemicals
Juglans species have diverse chemical constituents, including diarylheptanoids, quinones, polyphenols, flavones, and terpenes. The diarylheptanoids and quinones have notable antitumor activity in preclinical models, supplying lead compounds for preparing antitumor drugs. Total phenolic content analysis of walnut polyphenol extract has identified at least 16 unique phenols, including ellagitannins, quercetin, valoneic acid dilactone, and gallic acid.
3.5 Ellagitannin Metabolism: Urolithins
Among the most potent constituents of walnuts are the ellagitannins, primarily pedunculagin. After ingestion, the ellagitannins are hydrolyzed at low pH to release ellagic acid (EA), a non-flavonoid polyphenol that is subsequently metabolized by gut microbiota to bioactive urolithins (hydroxydibenzo[b,d]pyran-6-ones). Several urolithins, including urolithin A, reportedly have potent anti-inflammatory properties.
Dietary fiber in walnuts increases microbiota diversity, which contributes to the conversion of fiber into short-chain fatty acids (SCFAs).
4. Scientific Evidence by Health Area
4.1 Cardiovascular Health and Lipid Profiles
This is the most extensively researched and strongest area of clinical evidence for walnut consumption. A comprehensive search of PubMed and EMBASE databases of clinical trials comparing walnut-enriched diets with control diets yielded 26 clinical trials with a total of 1,059 participants for random-effects meta-analysis.
The weighted mean differences in reductions for walnut-enriched diets compared with control groups were −6.99 mg/dL (95% CI: −9.39, −4.58 mg/dL; P < 0.001) — a 3.25% greater reduction — for total blood cholesterol, and −5.51 mg/dL (95% CI: −7.72, −3.29 mg/dL; P < 0.001) — a 3.73% greater reduction — for LDL cholesterol. The trials examined participants aged 22–75 years, including those with high cholesterol, type 2 diabetes, metabolic syndrome, overweight or obesity, and healthy individuals. Walnut-enriched diets varied in amounts ranging from 5–24% of total calories per day (equivalent to approximately 0.5–3.9 ounces per day).
Compared to control diets, a diet supplemented with walnuts resulted in a significantly greater percent decrease in total cholesterol (3.25%), LDL cholesterol (3.73%), triglycerides (5.52%), and apolipoprotein B (4.19%). The meta-analysis concluded that incorporating walnuts into the diet improved the blood lipid profile without adversely affecting body weight or blood pressure.
The U.S. FDA has also approved qualified health claims for nuts (2003) and walnuts specifically (2004), though both claims were approved based on supportive but not conclusive evidence that consuming nuts and walnuts may reduce risk of coronary heart disease (CHD). The specific qualified health claim language for walnuts reads: "Supportive but not conclusive research shows that eating 1.5 ounces per day of walnuts, as part of a low saturated fat and low cholesterol diet and not resulting in increased caloric intake may reduce the risk of coronary heart disease."
Evidence strength: Strong for lipid-lowering effects, supported by multiple randomized controlled trials (RCTs) and systematic meta-analyses. The FDA qualified health claim reflects the consistent but not fully conclusive nature of this evidence in terms of hard cardiovascular endpoints (such as myocardial infarction or mortality).
4.2 Cognitive Function and Brain Health
The Walnuts and Healthy Aging (WAHA) study was designed as a two-center, randomized, 2-year clinical trial conducted in free-living, cognitively healthy elderly men and women. The study examined the effects of consuming 30–60 g/d walnuts on cognitive function using composite scores for memory, language, perception, frontal function, and global cognition.
In this 2-site randomized feeding trial, walnut supplementation at approximately 15% of daily energy intake for 2 years did not delay cognitive decline in community-dwelling elderly but cognitively healthy men and women. No significant differences were observed between walnut and control groups in adjusted mean change from baseline for all composite scores. However, post hoc analyses showed that among subjects from the Barcelona site, there were significant between-group differences in adjusted mean change for global cognition (p = .016) and perception (p = .005) composite scores, with the walnut group showing less decline than the control group over the two-year intervention period.
Clinical trial evidence from a small 8-week study in college students showed walnut consumption at 60 g/d improved inferential verbal reasoning compared with a control diet. Overall, there is abundant experimental evidence but limited clinical data on cognitive outcomes from walnut consumption.
Evidence strength: Mixed and preliminary in humans. The largest RCT (WAHA) found no overall significant effect on cognitive decline in healthy elderly, with only site-specific post hoc improvements. Evidence from animal and in vitro studies is more consistently positive but cannot be directly extrapolated to humans.
4.3 Gut Microbiome Modulation
A controlled-feeding, randomized crossover study was undertaken in healthy men and women (n = 18; mean age = 53.1 years; BMI 28.8 kg/m²). Study participants received isocaloric diets containing 0 or 42 g walnuts/d for two 3-week periods, with a 1-week washout between diet periods.
Walnut consumption affected the composition and function of the human gastrointestinal microbiota, increasing the relative abundances of Firmicutes species in butyrate-producing Clostridium clusters XIVa and IV, including Faecalibacterium and Roseburia, and reducing microbially derived, proinflammatory secondary bile acids and LDL cholesterol. The results suggest that the gastrointestinal microbiota may contribute to the underlying mechanisms of the beneficial health effects of walnut consumption.
There is a growing body of evidence that walnuts may contribute positively to the gut microbiome, having a prebiotic potential that promotes the growth of beneficial bacteria. Studies supporting this microbiome-modifying potential include both preclinical cancer models and several promising human clinical trials. Mediated both directly and indirectly via its actions on the microbiome, many of the beneficial properties of walnuts are related to anti-inflammatory properties, including effects on the immune system.
Evidence strength: Preliminary-to-moderate in humans. The key randomized crossover trial (42 g/d walnuts, n = 18) demonstrates a measurable effect on microbiota composition, but sample sizes are small and long-term clinical implications have not yet been fully established in larger trials.
4.4 Inflammation and Metabolic Syndrome
A systematic search in PubMed, EMBASE, Cochrane Library, Scopus, and ClinicalTrials.gov was performed to retrieve RCTs published through November 2021 reporting on outcomes of walnut consumption on metabolic syndrome and inflammatory markers in middle-aged and older adults, yielding 17 studies (11 crossover and 6 parallel trials) in the final selection.
One crossover RCT examined the effects of daily walnut consumption over 4 weeks on cardiometabolic parameters including lipid and glycemic profiles and soluble VCAM-1 levels in middle-aged individuals (48.81 ± 4.3 years) with at least one altered metabolic syndrome parameter, using 45 g of walnuts per day, with two 28-day intervention periods and a one-month washout period between them. A significant decrease in waist circumference (p = 0.049) was noted following walnut intake, along with a slight change in fasting blood glucose (p = 0.089).
In a parallel RCT targeting adults at risk of developing metabolic syndrome, assessment of changes following walnut and control-diet periods showed slight changes in oxidative stress and inflammation parameters but without any statistical significance among the 20 participants analyzed. Short-term (4-week) daily walnut consumption did not significantly alter oxidative stress and inflammation biomarkers, potentially contributing to maintenance of cellular homeostasis.
Evidence strength: Mixed. Lipid parameters show consistent improvement across multiple RCTs; effects on inflammatory biomarkers (CRP, TNF-α, IL-6) are inconsistent across studies, and positive findings in some trials are not replicated in others. Many individual trials are small and of short duration.
4.5 Cancer: Preclinical and Preliminary Human Evidence
Walnuts contain a remarkable array of natural constituents that may have additive and/or synergistic properties contributing to reduced cancer risk. There is a growing body of evidence that walnuts may contribute positively to the gut microbiome with prebiotic potential that promotes beneficial bacteria; studies supporting this microbiome-modifying potential include both preclinical cancer models and several promising human clinical trials.
Several studies consistently showed the antioxidant activity and anti-inflammation potential of the active compounds from tree nut kernels or by-products and their association with a reduced risk for CVD, T2D, cancer, and all-cause mortality.
Evidence strength: Predominantly preclinical (animal and in vitro). Human evidence for anticancer effects specific to walnut consumption is still limited and preliminary; no RCT has directly assessed walnut consumption as a cancer preventive or therapeutic intervention in humans with clinical cancer endpoints as primary outcomes.
4.6 Glycemic Control and Type 2 Diabetes
Clinical trials have reported beneficial effects of nut consumption on blood lipids, inflammatory parameters, insulin resistance, and blood pressure. A systematic analysis included 23 RCTs describing walnut doses of approximately 10–99 g/day in 1,948 subjects, as well as 10 cohort studies covering approximately 675,928 subjects, with outcomes assessed across blood lipids, cardiovascular function, inflammation- and hemostatic-related factors, markers of glucose metabolism, and body weight and composition.
Individual RCTs in participants with type 2 diabetes have shown modest improvements in fasting glucose and insulin markers with walnut-enriched diets, but evidence across trials is inconsistent, and no large definitive RCT focused exclusively on glycemic control in diabetic populations has produced unequivocal positive findings.
Evidence strength: Preliminary-to-moderate. Observational and smaller trial data suggest benefit; larger confirmatory RCTs are needed.
5. Body Systems and Health Areas Associated with Walnut
- Cardiovascular system: Lipid-lowering (LDL, total cholesterol, triglycerides, apolipoprotein B); endothelial function; anti-inflammatory and antioxidant effects on vascular tissue.
- Central nervous system: Cognitive function and age-related cognitive decline; brain health via omega-3 fatty acids (ALA→EPA/DHA) and polyphenols.
- Gastrointestinal system: Gut microbiome modulation; prebiotic fiber; production of short-chain fatty acids (SCFAs); secondary bile acid metabolism.
- Metabolic system: Glycemic control; insulin sensitivity; adiponectin levels; metabolic syndrome components including waist circumference.
- Immune and inflammatory system: NF-κB pathway inhibition; Nrf2/ARE activation; anti-inflammatory cytokine modulation (TNF-α, IL-6, CRP).
- Oncological (preclinical): Antitumor activity of juglone, diarylheptanoids, and quinones; urolithin A effects on cancer cell lines.
6. Dosage Forms and Dosages Reported in Studies
Dosages used in published clinical trials span a range depending on the outcome studied:
- Walnut-enriched diets in controlled trials have varied in amounts ranging from 5–24% of total calories per day (equivalent to approximately 0.5–3.9 ounces per day).
- In the microbiome crossover trial, participants received isocaloric diets containing 42 g walnuts per day for two 3-week periods.
- In the metabolic syndrome crossover RCT, participants were assigned to receive 45 g of walnuts per day within a controlled diet, with two 28-day intervention periods.
- In the WAHA study, the dosage examined was 30–60 g/d of walnuts for cognitive function assessment over a 2-year period.
- In a small 8-week study in college students, walnut consumption at 60 g/d was used.
- The FDA's qualified health claim specifically references 1.5 ounces per day (approximately 42.5 g) of walnuts.
Walnut is consumed primarily as a whole food rather than as an isolated supplement. Research preparations include whole raw kernels, cold-pressed walnut oil, and aqueous or ethanolic extracts of the husk and leaves used in more traditional or preclinical contexts.
7. Safety, Notable Considerations, and Interactions
7.1 Allergy and Cross-Reactivity
Tree nut allergy is common, with a global prevalence of up to 4.9%. Tree nut allergy is persistent in most patients, and accidental reactions are common. There is considerable clinical cross-reactivity between cashew and pistachio, and between walnut and pecan. True cross-reactivity is high between walnut and pecan (both members of the Juglandaceae family), which is relevant in oral immunotherapy — OIT to walnut can induce cross-desensitization to pecan.
Tree nut IgE-mediated reactions have the potential of being clinically severe and are one of the leading causes of fatal anaphylaxis. Walnut is one of the allergens responsible for nut allergy, particularly diffused in Europe, especially in the Mediterranean area. Immunoblotting assays have shown that 85% of walnut-allergic patients recognize Jug r 1 (walnut 2S albumin), which was associated with the development of severe symptoms.
7.2 Drug Interactions: Levothyroxine (Thyroid Hormone)
Walnuts' high fiber, phytate, and tannin content can lead to notable interactions with certain medications. The most well-established interaction is with thyroid replacement drugs like levothyroxine, where timing is a crucial factor to ensure proper absorption. Walnuts can interfere with the absorption of levothyroxine (Synthroid) due to their high fiber content. It is recommended to take thyroid medication on an empty stomach and wait at least four hours before eating walnuts.
7.3 Anticoagulant Considerations
For those on anticoagulant medications such as warfarin (Coumadin), managing vitamin K intake is a primary concern, as large fluctuations can affect treatment stability. Standard walnuts are generally considered safe and can be part of a healthy diet even while on blood thinners like warfarin, though consistency of intake is important. Walnut is not among the foods with a high vitamin K content that typically causes clinically significant interactions with warfarin; however, its polyphenol content and effects on lipid metabolism may be relevant in some contexts.
7.4 Caloric Density and Body Weight
Meta-analysis data confirm that incorporating walnuts into the diet improved blood lipid profiles without adversely affecting body weight. However, walnuts are calorically dense (~185 kcal per 28 g serving), and studies consistently note that the amounts tested were intended to substitute for — not add to — existing caloric intake. The FDA qualified health claim specifies that walnut consumption should not result in increased caloric intake.
7.5 Juglone Toxicity (Non-Kernel Parts)
The juglone compound's cancer-related inhibitory effects are associated with enhanced ROS production and lipid peroxidation, which at high doses in non-food concentrations represents a concern for cellular toxicity. Juglone is present predominantly in the husk, bark, and roots rather than in the edible kernel; consumption of the kernel at food-appropriate amounts is not associated with toxicity in published clinical trials. Use of concentrated husk or bark extracts at pharmacological doses requires caution, as the safety data for such preparations in humans are very limited.
7.6 Oxalate Content and Kidney Stone Risk
Walnuts contain moderate amounts of oxalates; individuals with a history of calcium oxalate kidney stones may need to account for this in high-quantity consumption, though this risk at typical food amounts (28–45 g/day) used in clinical trials has not been reported as clinically significant in the trials reviewed.
7.7 General Safety in Clinical Trials
In the 4-week metabolic syndrome crossover RCT, walnuts were well tolerated by all 20 participants who completed the intervention. Across the 26 trials included in the Harvard meta-analysis, no adverse effects on body weight or blood pressure were attributed to walnut-enriched diets, and no serious adverse events related to walnut consumption (beyond allergy in predisposed individuals) were reported.
References
Go back